Amonafide (BioDeep_00000858587)

   


代谢物信息卡片


Amonafide

化学式: C16H17N3O2 (283.1320702)
中文名称: 氨萘非特
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)N
InChI: InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
D000970 - Antineoplastic Agents
D004791 - Enzyme Inhibitors

同义名列表

1 个代谢物同义名

Amonafide



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Jing Xia, Yu Zhou, Siyue He, Manoj Kumar Vashisth, Huijie Jia, Qianlong Dai, Yufen He, Xiaobo Wang. Amonafide Induces HUVEC Senescence by Inhibiting Autophagy. Discovery medicine. 2023 06; 35(176):264-274. doi: 10.24976/discov.med.202335176.27. [PMID: 37272093]
  • A N Leaf, D Neuberg, E L Schwartz, S Wadler, P S Ritch, J P Dutcher, G L Adams. An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group. Investigational new drugs. 1997; 15(2):165-72. doi: 10.1023/a:1005823703909. [PMID: 9220297]
  • W Kreis, K Chan, D R Budman, S L Allen, D Fusco, A Mittelman, K Hock, S Akerman, A Calabro, C Puccio, M Spigelman. Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients. Cancer investigation. 1996; 14(4):320-7. doi: 10.3109/07357909609012158. [PMID: 8689426]
  • R S Witte, P Hsieh, P Elson, M M Oken, D L Trump. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Investigational new drugs. 1996; 14(4):409-13. doi: 10.1007/bf00180819. [PMID: 9157078]
  • M E Costanza, D Berry, I C Henderson, M J Ratain, K Wu, C Shapiro, D Duggan, J Kalra, I Berkowitz, A P Lyss. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Jul; 1(7):699-704. doi: NULL. [PMID: 9816035]
  • M J Ratain, G Rosner, S L Allen, M Costanza, D A Van Echo, I C Henderson, R L Schilsky. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Mar; 13(3):741-7. doi: 10.1200/jco.1995.13.3.741. [PMID: 7884434]
  • J A Benvenuto, D A Johnston, K Nishioka. The correlation of response with plasma pharmacokinetics and polyamine concentrations in patients with acute myelogenous leukemia receiving amonafide. Cancer letters. 1993 Jul; 70(3):175-9. doi: 10.1016/0304-3835(93)90228-2. [PMID: 8353813]
  • M J Ratain, R Mick, F Berezin, L Janisch, R L Schilsky, N J Vogelzang, L B Lane. Phase I study of amonafide dosing based on acetylator phenotype. Cancer research. 1993 May; 53(10 Suppl):2304-8. doi: NULL. [PMID: 8485716]
  • M J Ratain, R Mick, F Berezin, L Janisch, R L Schilsky, S F Williams, J Smiddy. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clinical pharmacology and therapeutics. 1991 Nov; 50(5 Pt 1):573-9. doi: 10.1038/clpt.1991.183. [PMID: 1934870]
  • C S Higano, P Goodman, J B Craig, J A Kish, S E Rivkin, M Wolf, E D Crawford. Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study. Investigational new drugs. 1991 Nov; 9(4):361-3. doi: 10.1007/bf00183582. [PMID: 1804814]
  • S O'Brien, J A Benvenuto, E Estey, M Beran, T B Felder, M Keating. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer research. 1991 Feb; 51(3):935-8. doi: NULL. [PMID: 1988134]
  • R Saez, J B Craig, J G Kuhn, G R Weiss, J Koeller, J Phillips, K Havlin, G Harman, J Hardy, T J Melink. Phase I clinical investigation of amonafide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989 Sep; 7(9):1351-8. doi: 10.1200/jco.1989.7.9.1351. [PMID: 2549205]
  • M J Ratain, A E Staubus, R L Schilsky, L Malspeis. Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer research. 1988 Jul; 48(14):4127-30. doi: NULL. [PMID: 3383202]
  • K Lu, M A McLean, M L Vestal, R A Newman. Pharmacokinetics of Amonafide in dogs. Cancer chemotherapy and pharmacology. 1988; 21(2):134-8. doi: 10.1007/bf00257359. [PMID: 3349561]
  • S S Legha, S Ring, M Raber, T B Felder, R A Newman, I H Krakoff. Phase I clinical investigation of benzisoquinolinedione. Cancer treatment reports. 1987 Dec; 71(12):1165-9. doi: NULL. [PMID: 3690526]
  • T B Felder, M A McLean, M L Vestal, K Lu, D Farquhar, S S Legha, R Shah, R A Newman. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. Drug metabolism and disposition: the biological fate of chemicals. 1987 Nov; 15(6):773-8. doi: NULL. [PMID: 2893701]
  • G Powis, D M Kroschel, D J Moore. Sensitive reversed-phase high-performance liquid chromatographic assay for the antitumor agent benzisoquinolinedione (Nafidimide) employing direct on-column injection of plasma and urine, and its use for pharmacokinetic studies in a dog. Journal of chromatography. 1985 Dec; 345(2):402-7. doi: 10.1016/0378-4347(85)80179-1. [PMID: 4086608]
  • K Lu, N Savaraj, R A Newman. High-performance liquid chromatographic separation and quantitation of benzisoquinolinedione (Nafidimide) from biological fluids. Journal of chromatography. 1985 Dec; 345(2):408-12. doi: 10.1016/0378-4347(85)80180-8. [PMID: 4086609]
  • A García Gancedo, C Gil-Fernández, P Vilas, S Pérez, F Rodriguez, E Paez, M F Braña, C M Roldán. Antiviral action of 5-amino-2-(2-dimethyl-aminoethyl)benzo-[de]-isoquinolin-1,3-dion e. Antiviral research. 1984 Aug; 4(4):201-10. doi: 10.1016/0166-3542(84)90018-4. [PMID: 6091540]